Penetration of anti-cancer agents into and throughout solid tumours is widely recognised as presenting a major limitation to their effectiveness. OxSonics Therapeutics’ proprietary platform technology, SonoTran®, is being developed to enable a step-change in the therapeutic index of anti-cancer agents by increasing their dose and distribution within solid tumours without any development costs or delays associated with their reformulation.
